Health Condition 1: L814- Other melanin hyperpigmentation Health Condition 2: L818- Other specified disorders of pigmentation Health Condition 3: L818- Other specified disorders of pigmentation
Conditions
Interventions
Intervention1: Topical Thiamidol: Topical Thiamidol is applied once daily for 12 weeks Clinical assessment will be done after every session of the treatment at 4weeks 8 weeks 12 weeks using MODIFIED
Sponsors
Dr Bandreddy Peranti
Eligibility
Inclusion criteria
Inclusion criteria: All females and males with Melasma aged above18 years Patients who are not on any other treatment for Melasma for past 1 month and patients who are advised to stop treatment for 1month Patients unresponsive to regular topical agents
Exclusion criteria
Exclusion criteria: Allergy or sensitivity to Thiamidol Active skin conditions or infections like eczema, dermatitis in the treatment area Recent laser or light based therapies Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of topical Thiamidol compared to triple combination therapy in patients with Melasma. Reduction in mMASI score indicating improvement in melasma severityTimepoint: Clinical assessment was performed using the Modified Melasma Area and Severity Index mMASI at baseline 4 weeks 8 weeks and 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcomes included the evaluation of side effects and patient tolerance to each therapy Timepoint: Clinical assessment was performed using the Modified Melasma Area and Severity Index mMASI at baseline 4 weeks 8 weeks and 12 weeks | — |
Countries
India
Contacts
Public ContactDr Bandreddy Peranti
Department of DVL ASRAM Hospital
Outcome results
None listed